Competition in Weight Loss Drug Space: Eli Lilly's Obesity Drug Succeeds In Two Late-Stage Studies, Shows About 26% Weight Loss

Eli Lilly And Co LLY announced the results of two phase 3 tirzepatide studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes

SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide compared to placebo. 

Across SURMOUNT-3 and SURMOUNT-4, participants on tirzepatide following intensive lifestyle intervention or with continued tirzepatide treatment achieved up to 26.6% mean weight loss for the efficacy estimandi.

The safety profile of tirzepatide in both studies was similar to previously reported SURMOUNT and SURPASS trials and to that of incretin-based therapies approved for treating obesity and overweight. T

The most commonly reported adverse events in both trials were gastrointestinal-related and generally mild to moderate in severity.

In the first study, SURMOUNT-3, Lilly’s drug helped reduce patients an additional 21.1% of weight, on average, after 12 weeks of lifestyle changes, including a low-calorie diet and exercise, compared to placebo, with a total mean weight loss of 26.6% from study entry over 84 weeks.

In the second study, SURMOUNT-4, Lilly’s drug helped patients reduce 21.1% weight, on average, compared to a placebo at the end of 36 weeks lead-in period and an additional 6.7% weight loss during a 52-week continued treatment period, for a total mean weight loss of 26.0% over 88 weeks.

Price Action: LLY shares are up 0.90% at $457.68 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!